MetabolicInvestigational

AOD-9604

Subcutaneous injection, Oral

Overview

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects.

Mechanism of Action

It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue..

Research Summary & Key Findings

Preclinical studies showed significant fat reduction without effects on IGF-1, glucose, or insulin levels. Phase 2b clinical trial showed modest but statistically significant weight reduction. TGA (Australia) approved as a food supplement. Limited Phase 3 clinical evidence.

Clinical Status

Investigational

AOD-9604 is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Subcutaneous injectionOral

Related Peptides in Metabolic

Find a Provider

Find a verified provider who offers AOD-9604 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply AOD-9604.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.